Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle" - Join Clinical Trial NCTNCT03588299

How to Join This Clinical Trial - NCTNCT03588299

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Hemophilia A. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Hemophilia A. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied: Hemophilia A
Treatment Being Tested: Investigational treatment
Study Phase: PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status: ACTIVE_NOT_RECRUITING
Study Identifier: NCTNCT03588299 - ClinicalTrials.gov Identifier
Sponsored By: Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

Initial screening to determine eligibility
Regular study visits and health assessments
Receiving the study treatment or placebo
Medical monitoring and follow-up care
Contributing to medical research that may help others
Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

Close medical monitoring by healthcare professionals
Access to potential new treatments
Compensation for time and travel (varies by study)
No-cost study-related medical care
The opportunity to help advance medical knowledge